A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Pharmacy

Comments

Moser JC, Opyrchal M, Rivera IR, Bilen MA, Curti B, Puzanov I, Morris K, Nirschl CJ, Park S, Bruno M, Windt P, Subramanian KK, Chopra SS, Isaacs R. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 737

This document is currently not available here.

Providence Full Text

Share

COinS